Pharmacogenetic Implications for Clinical Practice of Smoking CessationTreatment
سال انتشار: 1401
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 127
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
THMED04_012
تاریخ نمایه سازی: 19 اردیبهشت 1402
چکیده مقاله:
This is expected smoking to reach ۱.۶–۱.۹ billion by ۲۰۲۵. Only ۱۵–۳۰% of smokers continue toabstain from smoking. Hence, various quit efforts are often required. There is extensive proof thatsmoking persistence is inherited, and are determined by a multifaceted interaction of polygenicand environmental risk factors. Tobacco smoking is thought to be a multifactorial behaviourthrough genetic and environmental elements. It was shown that genetic factors justify roughly ۴۰–۷۵% of the variation in smoking initiation, ۷۰–۸۰% of the variation in smoking preservation,around ۵۰% of the difference in cessation achievement and ۳۰–۵۰% of the difference in risk ofwithdrawal symptoms. Variations in two comprehensive classes of candidate genes weresuggested to contribute to smoking behaviour, including; genes that likely impact the response tonicotine (nicotine metabolism, nicotinic receptors) and genes that may influence to addictivebehaviour because of key neurotransmitter pathways (dopamine and serotonin). Sincepharmacogenetic therapies for smoking cessation are usually administered at the variation of thepathways involved in smoking addiction, perhaps, this will influence the efficacy of these smokingcessation therapies as an emerging approach for individually tailored smoking cessation treatmentbased on genetic background. Therefore, a profile of genetic variants in these smoking-relatedpathways could possibly be used to expect earlier which smoking cessation therapy is likely to bemost effective. Perspective of the role that inherited variation plays in response topharmacotherapy could help physicians to personalize treatment type, dose, and duration based ongenotype, thus reducing adverse reactions, improving treatment compliance, and maximizingpharmacotherapy effectiveness.
کلیدواژه ها:
نویسندگان
Abdolazim Nejatizadeh
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of MedicalSciences, Bandar Abbas, Iran.